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Objective: To assess the prognostic value of new left bundle branch block (LBBB) in patients with acute
myocardial infarction (AMI).
Background: LBBB develops in many cardiac conditions, including AMI. The empirical evidence for the
contribution of LBBB to mortality in AMI is not consistent.
Methods: Medline, PubMed, CINAHL, and EMBASE were searched. Inverse variance meta-analysis was
performed with odds ratios as the effect estimates. The I2 statistic and risk of bias were assessed.
Results: Eight studies involving 105,861 participants were eligible. New LBBB was associated with higher
mortality at 30 days (OR: 2.10, 95% CI 1.27 to 3.48) and 1-year follow up (OR: 2.81, 95% CI 1.64 to 4.80),
and increased heart failure risk (OR: 2.64, 95% CI 1.84 to 3.77).
Conclusions: AMI patients with new LBBB are a high risk group and must be treated accordingly. Yet,
more research is needed given the limitations of studies.
 2016 Elsevier Inc. All rights reserved.Introduction
Many studies have shown that patients with acute myocardial
infarction (AMI) who present with bundle branch block (BBB) may
have a worse prognosis than AMI patients who have normal con-
duction.1e5 Yet investigators of these studies did not compare the
effects of right versus left BBB. A recent systematic review6 showed
that patients with right BBB and AMI were at more than 2-fold
higher risk of all-cause mortality at 30 days of follow up
compared to those with no block. On the other hand, the literature
on left bundle branch block (LBBB) is not consistent. Indeed, a
number of investigators of cohort studies found that LBBB is asso-
ciated with, and may be an independent predictor of highermerican University of Beirut,
All rights reserved.mortality among patients with AMI.7e14 However, other in-
vestigators did not ﬁnd LBBB to be an independent predictor of
mortality; they attributed the higher mortality in this population to
other risk factors and co-morbidities.15e18
The American Heart Association (AHA) and European Society of
Cardiology (ESC) in their guidelines consider AMI patients with
new LBBB a high risk group and recommend for their treatment
early reperfusion therapy with percutaneous coronary intervention
(PCI) or ﬁbrinolytic therapy.22,23 Yet both organizations acknowl-
edge that it is difﬁcult to diagnose ST elevation MI in the setting of
LBBB and ascertain whether the LBBB is old or new, considering
that oftentimes no prior ECG is available for comparison.19,20 Wong
et al21 found signiﬁcantly higher mortality rates in AMI patients
with deﬁnite new LBBB compared to those with no LBBB, but no
difference when LBBB was present at baseline versus no LBBB; this
suggests that the time of onset of LBBB is signiﬁcant in estimating
associated mortality. In light of the above, and in an attempt at
quantifying the independent contribution of new LBBB to patient
outcomes in AMI patients, we conducted a systematic review and
B. Al Rajoub et al. / Heart & Lung xxx (2016) 1e72meta-analysis in order to assess the prognostic value of new LBBB
in patients hospitalized with AMI, in terms of risk for 30-day and
one-year mortality, and risk of heart failure.
Methods
We published the protocol of this study in PROSPERO (Regis-
tration number: CRD42014015286). The eligibility criteria of the
included studies were:
 Design: Observational studies, including cohort and case e
control studies.
 Population: Patients with acute myocardial infarction.
 Exposure: New LBBB compared to no new LBBB.
 Outcomes: The primary outcomes were in-hospital mortality
(or mortality within 30 days) and one-year mortality. Sec-
ondary outcomes were heart failure, atrio-ventricular block2,243 Medline 
3,972 EMBASE 
2,216 CINAHL 
4,696 PubMed 
AŌer removing duplicates 9,399 remained 
361 remaining for full text review 
9 reported nLBBB 
1 by manual review 
8 included studies 
1 p
1 i
be
Fig. 1. Stud(AV block) that developed after LBBB, and placement of a
pacemaker. We included studies that reported adjusted or
unadjusted risk estimates.
This systematic review followed the PRISMA guidelines. We
decided to exclude from the analysis studies conducted prior to
1980 because the introduction of revascularization therapy, which
started in the 1980s, have led to signiﬁcant reduction in mortality
rates in AMI patients.22 Only 2 studies conducted prior to 1980 ﬁt
our inclusion criteria.
The ﬁrst author (B.A.) and a medical librarian searched PubMed,
Medline, EMBASE, and CINAHL starting the date of their inception.
The search terms for Medline were: myocardial infarction, bundle
branch block, prognosis, survival analysis, and related synonyms.
The full search strategy is provided in the online supplement. In
addition, the references cited in the included studies were screened
for relevance. No restrictions were made by language.9038 excluded by Ɵtle and abstract 
12 abstracts 
42 reported all LBBB (new/old) 
41 reported all BBB (Right & LeŌ) or right 
BBB only 
73 No enough data for eﬀect size on either 
nLBBB or comparison group 
63 Not a primary study (reviews or editorial 
leƩers) or case reports 
52 Focused on other subjects 
68 Non-English arƟcles published or 
conducted before 1980 
ublished before 1980 
denƟfied by manual review but was published 
fore 1980 
y ﬂow.
Table 1
Characteristics of included studies.
First author Study design/funding Sample
size
Patients Exposure Comparison Outcome Country
Miller et al.29 Cohort. Funding N.R. 907 Patients admitted to
CCU with AMI
Patients with AMI
and new LBBB
Patients with AMI
and normal conduction
In-hospital
mortality
USA
Widimsky
et al.28
Cohort. Partially
supported by
the Charles University
Prague research
project.
6742 Consecutive patients
with AMI who
underwent coronary
angiography
Patients with AMI
and new LBBB
Patients with AMI and
normal
conduction.
In-hospital
mortality
Czech
Republic
Wong et al.21 Cohort. The author
H.D.W. received
partial support from the
Green
Lane Research and
Educational
Fund Board.
15,365 Secondary analysis of
HERO- 2 trial data
Patients with AMI
and new LBBB
Patients with AMI and
normal
conduction
In-hospital
mortality
46
countries
Yeo et al.18 Cohort. Multiple
funding sources
for different authors.
46,006 Data from the ACTION-
GWTG registry
Patients with AMI
and new LBBB
Patients with STEMI
without
LBBB
In-hospital
mortality
HF
USA
Mijailovic
et al.26
Cohort. Funding N.R 577 Consecutive patients
admitted to CCU with
AMI
Patients with AMI
and new LBBB
Patients with AMI and
normal
conduction
In-hospital
mortality
Serbia
Brown et al.25 Cohort. Funding N.R. 1445 Patients presenting for
PPCI at one
Tertiary referral center
Patients with AMI
and new LBBB
Patients with STEMI
without
LBBB
One-year
mortality
UK
Al-Faleh et al.27 Cohort. Funding N.R. 22,839 Data from 2 trials
(ASSENT 2 and 3 trials)
Patients with AMI
and new LBBB
Patients with AMI and
normal
conduction
In-hospital and
one-year
mortality, HF
29 countries
Juarez-Herrera
et al.30
Cohort. Funding N.R. 4237 Data from registry of
the Mexican Cardiology
Society
Subgroup of patients
with AMI and
new LBBB
Patients with AMI and
normal conduction
In-hospital
mortality
Mexico
Total: 105,861
Legend: N.R.: Not reported. ACTION-GWTG: National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network RegistryeGet With the
Guidelines; AMI: Acute Myocardial Infarction. CCU: Coronary Care Unit; LBBB: Left Bundle Branch Block. STEMI: ST Elevation Myocardial Infarction. HF: Heart Failure. UK:
United Kingdom.
B. Al Rajoub et al. / Heart & Lung xxx (2016) 1e7 3In the ﬁrst round, we screened the titles and abstracts of all the
citations identiﬁed in the search. The primary investigator screened
all references, and ﬁve other team members screened the same
references in duplicate and independently. We obtained the full
text articles for the citations that were judged as potentially eligible
by at least one reviewer. Then, we screened these full text articles
for eligibility in duplicate and independently, using a standardized
screening form. Results were compared and disagreements were
resolved by discussion and in consultation with a senior
author (E. A.).
Two of the authors (B. A. and S. N.) abstracted the data inde-
pendently using a standardized form. Disagreements were resolved
with the help of a third author (E. A.). For each study, the following
data were extracted: surname of the ﬁrst author, year of publica-
tion; study design, source of funding, country of origin, descriptionFig. 2. Mortalityof the sample, exposure group, comparison group, outcome mea-
sures and reported effect sizes. We extracted both adjusted and
unadjusted estimates when available.
We also assessed the risk of bias in each study based on the
appropriateness of the determination of inclusion and exclusion
criteria, validity of the exposure measure, validity of the outcome
measure, control for confounding variables and completeness of
data using the GRADE guidelines.23
We present the effect sizes as odds ratios (OR) with corre-
sponding conﬁdence intervals (CI) because most of the included
studies either reported effect sizes as odds ratios, or reported data
from which it was possible to calculate OR and CI. We pooled the
effect sizes across studies using an inverse variance meta-analysis
and the random effect model. We generated for each outcome a
forest plot to display the individual study OR and 95% CI, as well asat 30 days.
Fig. 3. Adjusted 30 days mortality.
B. Al Rajoub et al. / Heart & Lung xxx (2016) 1e74the summary OR and 95% CI. In addition, we conducted a sensitivity
meta-analysis for the 30-day mortality outcome restricted to
studies that reported adjusted effect estimates.
Wong et al21 presented effect size data for one group of 300
patients with LBBB at baseline that was classiﬁed as presumed new
LBBB, and another group of 25 patients who developed LBBBwithin
60 min of receipt of therapy and were considered deﬁnite new
LBBB. We used the effect estimate of the deﬁnite new LBBB21 group
for that study in themain analysis.We also did a sensitivity analysis
using the effect estimate for the groupwith LBBB at baseline21; that
summary effect size was not statistically signiﬁcant (OR: 1.28; 95%
CI: 0.84 to 1.97).
We assessed heterogeneity among the included studies using
the I-squared statistic. We considered an I2 value greater than 50%
as indicative of substantial heterogeneity.24 We conducted the
analyses using RevMan Analyses version 5.3 (Nordic Cochrane
Center, Ringshopitalet 2014).
Results
Fig. 1 shows the study ﬂow, including the number of excluded
studies and reasons for exclusion. Of the 9399 citations identiﬁed
by the search strategy, 8 articles reporting observational cohort
studies met the inclusion criteria.18,21,25e30 One of the studies was
published in the Serbian language, whereas the remaining ones
were in English. Among the studies published before 1980 that
were excluded, only 2 reported about new LBBB.
Table 1 summarizes the characteristics of the 8 included
studies. The studies were conducted in the following countries:
the USA (n ¼ 2), Czech Republic (n ¼ 1), Serbia (n ¼ 1), the UK
(n ¼ 1), Mexico (n ¼ 1), and in more than 1 country (n ¼ 2). The
sample size ranged from 57731 to 46,006.21 The total number ofFig. 4. One-yeaparticipants in all the studies combined was 105,861. All the
studies used the cohort design, including 2 that used registry
data, 2 that were secondary analyses of data from clinical trials
registries, and 4 that included consecutive patients admitted to
referral centers for angiography or to coronary care unit. Seven
studies reported in-hospital mortality, 2 reported one-year mor-
tality, and 2 reported on heart failure. None of the studies
reported on the occurrence of AV block or placement of a pace-
maker as outcomes.
The meta-analysis of all 7 studies that reported effect estimates
(adjusted and unadjusted) on 30-day mortality found an OR of 2.10
(95% CI 1.27 to 3.48) for the association between new LBBB and all-
cause mortality at 30 days of follow up (Fig. 2).
We performed sensitivity analysis by conducting a meta-
analysis for the 5 studies that reported adjusted effect sizes; here
also, new LBBB was signiﬁcantly associated with increased risk of
all-causemortality within 30 days (OR: 1.73, 95% CI: 1.04 to 2.88), as
shown in Fig. 3. The I2 statistic showed substantial heterogeneity
among the studies that reported 30-day mortality. The I2 was 79%
and 85% for studies that reported adjusted effect estimates and
those that reported adjusted and unadjusted effect estimates,
respectively.
The meta-analysis of the 2 studies that reported effect estimates
on one-year mortality found an OR of 2.81 (95% CI: 1.64 to 4.80) for
the association between new LBBB and all-cause mortality (Fig. 4).
The test of heterogeneity showed no signiﬁcant heterogeneity
(I2 ¼ 4%).
Only 2 studies reported data on heart failure (Fig. 5). The sum-
mary effect estimate derived from these 2 studies showed an
increased risk of developing heart failure in patients who present
with AMI and new LBBB (OR: 2.64; 95% CI: 1.84 to 3.77). Therewas a
substantial heterogeneity between those two studies (I2 ¼ 79%).r mortality.
Fig. 5. Heart failure.
B. Al Rajoub et al. / Heart & Lung xxx (2016) 1e7 5Two authors (B.A. and S.N.) assessed the risk of bias indepen-
dently using the GRADE guidelines23 and discrepancies were
resolved by discussion. The results of the assessment of the risk of
bias for each study and the overall risk of bias in all studies are
shown in Figs. 6 and 7, respectively. The main biases were in the
sample eligibility in half of the studies and the lack of adjustment
for confounding variables in three studies. For example, Al-Faleh
et al27 included a select group of participants who were enrolled
in 2 trials that tested different thrombolytic agents but the odds
ratio calculated were adjusted for many confounders. On the other
hand, Brown et al25 included consecutive patients referred for
primary PCI at a single tertiary referral center, but the authors failed
to adjust for confounders. Moreover, the exposure measure was
unclear in 2 studies.18,26Discussion
In summary, we identiﬁed 8 studies with a total of 105,861
patients that evaluated the prognostic value of a new LBBB inFig. 6. Risk of bias of individual studies.patients with AMI. The results show that new LBBB is associated
with increased risk of 30-day mortality, 1-year mortality and
development of heart failure in patients with AMI.
This study has a number of strengths. First, and to the best of our
knowledge, this is the ﬁrst meta-analysis of observational studies
on the prognostic value of new LBBB in the context of AMI. Second,
we followed a systematic methodology with a very comprehensive
search, using duplicate study selection and data extraction, and a
formal assessment of the risk of bias of all the included studies. Our
ﬁndings reﬂect the gap of knowledge in this area, as only 8 studies
were found.
The ﬁndings related to mortality suggest a higher risk in AMI
patients with new LBBB, thus lending support to the continued
application of the treatment guidelines for this population,19,20
although these recommendations were based on earlier
studies.31 LBBB may progress to complete atrio-ventricular block,
bradyarrhythmias, torsades de pointes and sudden cardiac death,
which could explain the ﬁndings.32 It is worth noting that het-
erogeneity for the studies that reported 30-day mortality was
high, which can be the result of many factors. The included
studies involved patients from different settings, including select
groups of patients in two studies. In addition, variation in the
treatment modalities may have a substantial impact on the out-
comes. Some studies involved patients who underwent PCI
whereas others had patients who received thrombolytic medi-
cations that included Streptokinase, Tenecteplase, and Alteplase.
In some of the included studies the treatment used in those pa-
tients was not even described. Moreover, the time from the onset
of symptoms to receipt of the treatment may have a substantial
impact as well.32
In few cases, the determination or criteria for LBBB were not
clearly described. Some authors reported using the criteria by
Sgarbossa et al,33 whereas others mentioned wide QRS and the
shape of LBBB as diagnostic criteria. The Sgarbossa diagnostic
criteria are limited by their lack of sensitivity.34 Moreover, diag-
nosing AMI in the presence of LBBB is challenging because ST
elevation may not be present. Still LBBB, in case of troponin
elevation but no ST segment elevation, may represent a marker of
illness severity and these patients must be considered for angiog-
raphy and possible PCI. In case Troponin is negative, the ESC
guidelines recommend repeating Troponin 1e2 h following
symptom onset when BBB is of uncertain origin, in order to help
decidewhether or not to do coronary angiography and PCI.19 In case
the initial ECG is negative, it must be repeated or ST segmented
monitored.19
Effect estimates of the risk of developing heart failure were
provided in only 2 studies.18,26 There was a statistically signiﬁcant
increase in the risk of heart failure in patients with new LBBB;
however there was substantial heterogeneity between these
studies (OR: 2.64 95% CI 1.84 to 3.77; I2 ¼ 79%). Thus this summary
effect should be interpreted with caution because the investigators
of both studies did not report the criteria used to diagnose heart
failure. In addition, they did not account for other risk factors that
Fig. 7. Overall risk of bias.
B. Al Rajoub et al. / Heart & Lung xxx (2016) 1e76may lead to the development of heart failure, such as congenital
heart defects, infections, some diabetes medications and alcohol
consumption.
Limitations
This analysis has a number of limitations. The number of
studies21,25e30 that met the inclusion criteria was small. In addition,
the studies were heterogeneous in terms of the included partici-
pants and the treatments used, which could have inﬂuenced the
outcomes. One important consideration in this area of study is the
time of onset of LBBB, whether old or new, in relation to the AMI in
order to isolate the prognostic impact of the LBBB. Unfortunately,
the majority of the published studies on LBBB did not differentiate
between old and new onset LBBB, which led to our small sample
size. Another point worth considering is the deﬁnition of AMI,
which has been modiﬁed since 1980, adding to the heterogeneity
among studies. Moreover, a number of the included studies were
prone to a high risk of bias, thus inﬂuencing the results. The relative
prognostic value of new LBBB compared to old LBBB or RBBB, which
could have enriched the ﬁndings, could not be addressed due to the
lack of such data. Alternative outcomes such as cardiac mortality or
major adverse cardiac events (MACE) were not measured in the
reviewed studies; this gap can be addressed in future studies.
Future research in this area would beneﬁt from rigorous studies
with representative samples of patients with AMI and more
consistent control over confounders. The variability in treatment
modalities and time to treatment initiation must be accounted for
in the study design and data analysis. Future research should also
focus more on the actual onset of LBBB (old or new) and compare
outcomes of AMI patients by time of onset of LBBB. Other compli-
cations that may follow this kind of conduction abnormality, such
as AV block and heart failure must be studied as these have sig-
niﬁcant implications on the patients’ quality of life and clinical
outcome. Additional outcomes that investigators of the impact of
new LBBB in patients with AMI ought to address include MACE and
cardiac mortality.
In terms of clinical practice, one recommendation would be to
monitor patients admitted with AMI for LBBB, as is done with ST
segment monitoring, then report and document the onset of new
LBBB in the medical record so that treatment is revised accordingly.
Moreover, clinicians need to revisit the diagnostic criteria for LBBB
in order to enhance its diagnostic accuracy and subsequent treat-
ment adequacy of AMI patients.
In conclusion, although the ﬁndings of this meta-analysis
support the current guidelines by the ACC/AHA and the
ESC19,20 in recommending treatment with early reperfusiontherapy (PCI or thrombolytic therapy) of patients who present
with new LBBB in the context of AMI, continued monitoring
for new LBBB and future studies with stronger designs can sub-
stantiate the body of empirical evidence for the prognostic value
of new onset LBBB.Appendix. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.hrtlng.2016.11.002.References
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